<!DOCTYPE html><html xmlns="http://www.w3.org/1999/xhtml" xmlns:epub="http://www.idpf.org/2007/ops" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd">
<head>
<meta http-equiv="default-style" content="text/html; charset=utf-8" />
<title>Campbell-Walsh-Wein Urology Twelfth Edition Review</title>
<link rel="stylesheet" type="text/css" href="../../style/Elsevier_eBook.css" />
<link rel="stylesheet" type="text/css" media="only screen" href="../../style/media.css" />
  

<link rel="stylesheet" type="text/css" href="../../widgets/common_assets/css/common.css" />
<link rel="stylesheet" type="text/css" href="../../widgets/common_assets/css/variables.css" />
<script type="text/javascript" src="../../widgets/common_assets/scripts/mathjax/tex-mml-chtml.js"></script>
<script type="text/javascript" src="../../widgets/common_assets/scripts/common.js"></script>
<script type="text/javascript" src="../../widgets/img_lightbox_handler/img_lightbox_data.js"></script>
<script type="text/javascript" src="../../widgets/img_lightbox_handler/img_lightbox_parent.js"></script>
</head>
<body>
<section epub:type="chapter">
<a id="c0076"></a>
<header>
<div id="CN">76</div>
<h1 class="chaptitle" epub:type="title" id="B9780323639699000768">Neoplasms of the Testis</h1>
<address>
<div class="chapau" id="augrp0010">Andrew J. Stephenson, and Timothy D. Gilligan</div>
</address>
</header>
<section>
<h3 class="h2hd" id="cesectitle0010">Keywords</h3>
<div class="keywords">carcinoma; embryonal; drug therapy; endodermal sinus tumor; lymph node excision; neoplasm recurrence; neoplasm staging; radiotherapy; seminoma; teratoma; testicular neoplasms; testis; watchful waiting</div>
</section>
<section>
<section>
<a id="s0011"></a>
<iframe src="../../widgets/MCMS/xhtml/ch076_assessments.xhtml" height="710"></iframe>
<div id="p0010"></div>


 
</section><span id="pagebreak_285"></span><span id="pagebreak_286"></span>
<section>
<a id="s0010"></a>
<h2 class="h1hd" id="cesectitle0020">Pathology</h2>
<a id="s0015"></a>
<div id="p0850"></div>
<div>
<ul class="ce_list" id="olist0150">
<li class="numlist" id="p0855">
    <a id="s0020"></a>
<a id="o0845"></a>1. A 26-year-old man has a right radical orchiectomy for an embryonal carcinoma of the testis. At the time of surgery, a contralateral biopsy is performed and reveals intratubular germ cell neoplasia (<a href="#f0013">Fig. 76.1</a>). The patient should be advised that he:</li>



<li class="numlist">
<ul class="ce_list" id="olist0155">
<li class="numlist1" id="p0860">
<a id="o0850"></a>a. should have a radical orchiectomy.</li>
<li class="numlist1" id="p0865">
<a id="o0855"></a>b. has a significant chance of developing a germ cell tumor in the left testis.</li>
<li class="numlist1" id="p0870">
<a id="o0860"></a>c. should not try to have a child.</li>
<li class="numlist1" id="p0875">
<a id="o0865"></a>d. should immediately receive radiation to the testis.</li>
<li class="numlist1" id="p0880">
<a id="o0870"></a>e. should receive salvage chemotherapy.</li>
</ul>
</li>
<li class="numlist">
<a id="pg287"></a>
</li>
<li>
<span epub:type="pagebreak" title="287" id="pagebreak_287"></span>
</li>
<li id="sf0011">
<div class="pageavoid">
<figure class="fig" id="f0013">
<img src="../../IMAGES/B9780323639699000768/main.assets/f76-01-9780323639699.jpg" alt="image" />
<figcaption class="figleg">
<span class="fignum">Fig. 76.1</span>
<br />
<span class="figcredit">From Bostwick DG, Cheng L: <span class="italic">Urologic surgical pathology</span>, ed 2, Edinburgh, 2008, Mosby.</span>
</figcaption>
</figure>
</div>
</li>
<li class="numlist" id="p0885">
<a id="o0875"></a>2. A 35-year-old man has an asymptomatic right scrotal mass. Testicular ultrasonography reveals a 3-cm heterogeneous intratesticular mass. A right radical orchiectomy is performed. The histology is depicted in <a href="#f0017">Fig. 76.2</a> and is reported as seminoma. Abdominal CT scan is normal. The patient should be advised to:</li>
<li class="numlist">
<ul class="ce_list" id="olist0160">
<li class="numlist1" id="p0890">
<a id="o0880"></a>a. receive radiation to the contralateral testis.</li>
<li class="numlist1" id="p0895">
<a id="o0885"></a>b. receive at least four cycles of chemotherapy.</li>
<li class="numlist1" id="p0900">
<a id="o0890"></a>c. be advised that observation is not an option.</li>
<li class="numlist1" id="p0905">
<a id="o0895"></a>d. be advised to have radiation therapy to the retroperitoneum.</li>
<li class="numlist1" id="p0910">
<a id="o0900"></a>e. receive radiation to the abdomen and chest.</li>
</ul>
</li>
<li class="numlist" id="p0915">
<a id="o0905"></a>3. A 32-year-old man has a right radical orchiectomy for a testicular mass. Preoperatively, his AFP value was normal and his hCG level was elevated at 5000 units. The histology is depicted in <a href="#f0022">Fig. 76.3</a> and is reported as seminoma with giant cells. The next step in management is:</li>
<li class="numlist">
<ul class="ce_list" id="olist0165">
<li class="numlist1" id="p0920">
<a id="o0910"></a>a. follow markers and check half-life.</li>
<li class="numlist1" id="p0925">
<a id="o0915"></a>b. chemotherapy according to choriocarcinoma protocol.</li>
<li class="numlist1" id="p0930">
<a id="o0920"></a>c. RPLND.</li>
<li class="numlist1" id="p0935">
<a id="o0925"></a>d. radiation therapy to retroperitoneum.</li>
<li class="numlist1" id="p0940">
<a id="o0930"></a>e. three cycles of chemotherapy.</li>
</ul>
</li>
<li class="numlist" id="p0945">
<a id="o0935"></a>4. A 50-year-old man has a right radical orchiectomy for a testicular mass. The histology is depicted in <a href="#f0026">Fig. 76.4</a> and is a spermatocytic tumor. Abdominal and chest CT are negative. Serum markers are normal. The patient should be advised to:</li>
<li class="numlist">
<ul class="ce_list" id="olist0170">
<li class="numlist1" id="p0950">
<a id="o0940"></a>a. receive radiation to the retroperitoneum.</li>
<li class="numlist1" id="p0955">
<a id="o0945"></a>b. receive one cycle of chemotherapy.</li>
<li class="numlist1" id="p0960">
<a id="o0950"></a>c. have a biopsy of the contralateral testis.</li>
<li class="numlist1" id="p0965">
<a id="o0955"></a>d. not have any treatment.</li>
<li class="numlist1" id="p0970">
<a id="o0960"></a>e. have a PET-CT scan.</li>
</ul>
</li>
<li class="numlist" id="p0975">
<a id="o0965"></a>5. A 20-year-old man has a right radical orchiectomy. The pathology is depicted in <a href="#f0031">Fig. 76.5</a> and is read as embryonal carcinoma. His hCG and AFP values are elevated and a CT of abdomen and chest reveals no evidence of metastatic disease. Three weeks later, repeat AFP and hCG testing show no change in either marker. The patient should be advised to:</li>
<li class="numlist">
<ul class="ce_list" id="olist0175">
<li class="numlist1" id="p0980">
<a id="o0970"></a>a. have induction chemotherapy.</li>
<li id="sf0016">
<div class="pageavoid">
<figure class="fig" id="f0017">
<img src="../../IMAGES/B9780323639699000768/main.assets/f76-02-9780323639699.jpg" alt="image" />
<figcaption class="figleg">
<span class="fignum">Fig. 76.2</span>
<br />
<span class="figcredit">From Bostwick DG, Cheng L: <span class="italic">Urologic surgical pathology</span>, ed 2, Edinburgh, 2008, Mosby.</span>
</figcaption>
</figure>
</div>
</li>
<li id="sf0021">
<div class="pageavoid">
<figure class="fig" id="f0022">
<img src="../../IMAGES/B9780323639699000768/main.assets/f76-03-9780323639699.jpg" alt="image" />
<figcaption class="figleg">
<span class="fignum">Fig. 76.3</span>
<br />
<span class="figcredit">From Bostwick DG, Cheng L: <span class="italic">Urologic surgical pathology</span>, ed 2, Edinburgh, 2008, Mosby.</span>
</figcaption>
</figure>
</div>
</li>
<li class="numlist1" id="p0985">
<a id="o0975"></a>b. have an RPLND.</li>
<li class="numlist1" id="p0990">
<a id="o0980"></a>c. have a PET-CT.</li>
<li class="numlist1" id="p0995">
<a id="o0985"></a>d. receive radiotherapy below the diaphragm.</li>
<li class="numlist1" id="p1000">
<a id="o0990"></a>e. repeat the hCG and AFP tests in another month.</li>
</ul>
</li>
<li class="numlist" id="p1005">
<a id="o0995"></a>6. A 25-year-old man has a right radical orchiectomy. The histology is depicted in <a href="#f0037">Fig. 76.6</a> and is reported as a mature teratoma. The patient’s AFP is slightly elevated and bHCG is negative; <span epub:type="pagebreak" title="288" id="pagebreak_288"></span>
<a id="pg288"></a>however, there is a 3-cm mass in the retroperitoneum on CT. He is given chemotherapy and the mass shrinks to 1.8 cm. The patient should be advised to:</li>
<li>
<div class="pageavoid">
<figure class="fig" id="f0026">
<img src="../../IMAGES/B9780323639699000768/main.assets/f76-04-9780323639699.jpg" alt="image" />
<figcaption class="figleg">
<span class="fignum">Fig. 76.4</span>
<br />
<span class="figcredit">From Bostwick DG, Cheng L: <span class="italic">Urologic surgical pathology</span>, ed 2, Edinburgh, 2008, Mosby.</span>
</figcaption>
</figure>
</div>
</li>
<li>
<div class="pageavoid">
<figure class="fig" id="f0031">
<img src="../../IMAGES/B9780323639699000768/main.assets/f76-05-9780323639699.jpg" alt="image" />
<figcaption class="figleg">
<span class="fignum">Fig. 76.5</span>
<br />
<span class="figcredit">From Bostwick DG, Cheng L: <span class="italic">Urologic surgical pathology</span>, ed 2, Edinburgh, 2008, Mosby.</span>
</figcaption>
</figure>
</div>
</li>
<li class="numlist">
<ul class="ce_list" id="olist0180">
<li class="numlist1" id="p1010">
<a id="o1000"></a>a. have a retroperitoneal lymphadenectomy dissection (RPLND).</li>
<li class="numlist1" id="p1015">
<a id="o1005"></a>b. have salvage chemotherapy.</li>
<li class="numlist1" id="p1020">
<a id="o1010"></a>c. get an FDG-PET scan.</li>
<li class="numlist1" id="p1025">
<a id="o1015"></a>d. receive radiation therapy.</li>
<li class="numlist1" id="p1030">
<a id="o1020"></a>e. be observed.</li>
</ul>
</li>
</ul>
</div>
</section>
<section>
<a id="sf0036"></a>
<div class="pageavoid">
<figure class="fig" id="f0037">
<img src="../../IMAGES/B9780323639699000768/main.assets/f76-06-9780323639699.jpg" alt="image" />
<figcaption class="figleg">
<span class="fignum">Fig. 76.6</span>
<br />
<span class="figcredit">From Bostwick DG, Cheng L: <span class="italic">Urologic surgical pathology</span>, ed 2, Edinburgh, 2008, Mosby.</span>
</figcaption>
</figure>
</div>
</section>
<section>
<h2 class="h1hd" id="cesectitle0025">Imaging</h2>
<div id="p1035"></div>
<div>
<ul class="ce_list" id="olist0185">
<li class="numlist" id="p1040">
<a id="o1025"></a>1. A 36-year-old man noted a firm left scrotal mass. He was hit in the groin 1 month earlier with a tennis ball. Currently he has no pain, fever, or chills. The testicular ultrasound image is depicted in <a href="#f0042">Fig. 76.7</a>. The most likely diagnosis is:</li>
<li class="numlist">
<ul class="ce_list" id="olist0190">
<li class="numlist1" id="p1045">
<a id="o1030"></a>a. ruptured testis with peritesticular hematoma.</li>
<li class="numlist1" id="p1050">
<a id="o1035"></a>b. testicular neoplasm.</li>
<li class="numlist1" id="p1055">
<a id="o1040"></a>c. epidermoid cyst.</li>
<li class="numlist1" id="p1060">
<a id="o1045"></a>d. dilated rete testis.</li>
<li class="numlist1" id="p1065">
<a id="o1050"></a>e. testicular abscess.</li>
</ul>
</li>
<li class="numlist" id="p1070">
<a id="o1055"></a>2. A 32-year-old man had a left radical orchiectomy. Pathologic evaluation reveals a mixed GCT containing seminoma and embryonal cell carcinoma. Tumor markers are negative. The CT image depicted in <a href="#f0047">Fig. 76.8</a> was obtained 1-day postoperation. Chest CT is negative. The next step in management is:</li>
<li class="numlist">
<ul class="ce_list" id="olist0195">
<li class="numlist1" id="p1075">
<a id="o1060"></a>a. biopsy.</li>
<li class="numlist1" id="p1080">
<a id="o1065"></a>b. radiation therapy.</li>
<li class="numlist1" id="p1085">
<a id="o1070"></a>c. chemotherapy.</li>
<li class="numlist1" id="p1090">
<a id="o1075"></a>d. RPLND.</li>
<li class="numlist1" id="p1095">
<a id="o1080"></a>e. repeat CT in 1 week to confirm a postsurgical inflammatory response.</li>
</ul>
</li>
</ul>
</div>
</section>
<section>
    <a id="s0025"></a>
    
 
<div id="p1100"></div>
<div>
 
</div>
</section><span id="pagebreak_289"></span><span id="pagebreak_290"></span>
<section>
    <a id="s0026"></a>
<h2 class="h1hd" id="cesectitle0035">Pathology</h2>
<div id="p1240"></div>
<div>
<ul class="ce_list" id="olist0205">
<li class="numlist" id="p1245">
<a id="o1220"></a>1. <span class="bold">b. Has a significant chance of developing a germ cell tumor in the left testis.</span> The figure illustrates germ cell neoplasia in situ as evidenced by enlarged hyperchromatic nuclei and a lack of a spermatogenesis. <span class="bold">This carries a 50% risk of developing a germ cell tumor.</span>
</li>
<li class="numlist" id="p1250">
<a id="o1225"></a>2. <span class="bold">d. Be advised to have radiation therapy to the retroperitoneum.</span> Notice in the figure the sheathlike pattern of small cells interspersed with fibrous septa that contain lymphocytes, the hallmarks of seminoma. Although observation is an option, most would recommend radiation to the retroperitoneum, because seminoma is very sensitive to radiation and the morbidity <span epub:type="pagebreak" title="291" id="pagebreak_291"></span>
<a id="pg291"></a>is low—although there is a risk for the development of secondary malignancies over the long term.</li>
<li class="numlist" id="p1255">
<a id="o1230"></a>3. <span class="bold">a. Follow markers and check half-life.</span> The figure demonstrates seminoma with syncytiotrophoblasts. Approximately 15% of patients with seminoma have elevated hCG and will demonstrate syncytiotrophoblasts. Following orchiectomy, the hCG should decline according to its 24-hour half-life. This should be determined first before any treatment decisions are made.</li>
<li class="numlist" id="p1260">
<a id="o1235"></a>4. <span class="bold">d. Not have any treatment.</span> The figure shows a spermatocytic tumor that has a very low malignant potential. Notice the small basophilic cells and the multinucleated tumor giant cell, which are characteristic for spermatocytic tumor.</li>
<li class="numlist" id="p1265">
<a id="o1240"></a>5. <span class="bold">a. Have induction chemotherapy.</span> This patient has an embryonal carcinoma: notice the primitive, anaplastic epithelial cells. With persistently elevated serum markers, the patient should undergo induction chemotherapy. Surgery is not indicated, radiation therapy is inappropriate, and there is no reason to delay.</li>
<li class="numlist" id="p1270">
<a id="o1245"></a>6. <span class="bold">a. Have an retroperitoneal lymphadenectomy dissection (RPLND).</span> The tumor depicted is a teratoma: notice the mature enteric epithelium. Because the specimen is in the primary tumor, there is a high likelihood that there is residual teratoma in the retroperitoneal mass. This tumor is chemoinsensitive and should be resected.</li>
</ul>
</div>
</section>
<section>
    <a id="s0030"></a>
<a id="s0035"></a>
<h2 class="h1hd" id="cesectitle0040">Imaging</h2>
<div id="p1275"></div>
<div>
<ul class="ce_list" id="olist0210">
<li class="numlist" id="p1280">
<a id="o1250"></a>1. <span class="bold">b. Testicular neoplasm.</span> The ultrasound image shows an irregular vascular mass in the left testis that also has microlithiasis. This is most consistent with a testicular neoplasm. It is not unusual for patients to have a history of groin trauma before presentation.</li>
<li class="numlist" id="p1285">
<a id="o1255"></a>2. <span class="bold">c. Chemotherapy.</span> The CT image shows a large (&gt;5 cm) para-aortic mass that represents metastatic adenopathy. Because this represents bulky retroperitoneal disease (stage IIC), chemotherapy is the best option.</li>
</ul>
</div>
<div>

<div class="boxg1" id="b0010">
<p></p>
<div class="b1title" epub:type="title" id="title5050">Chapter Review</div>
<div id="bpar0010"></div>
<div>
<ul class="ce_list" id="olist0215">
<li class="b1numlist" id="bpar0015">
<a id="o1260"></a>1. GCTs occur bilaterally approximately 2% of the time. The risk factors for developing GCTs include cryptorchidism, a family history of testicular cancer, a previous history of testicular cancer, and GCNIS.</li>
<li class="b1numlist" id="bpar0020">
<a id="o1265"></a>2. In men with a history of GCTs, the finding of testicular microlithiasis on ultrasonography in the contralateral testis is associated with an increased risk of intratubular germ cell neoplasia; the significance of microlithiasis in the general population, however, is unclear.</li>
<li class="b1numlist" id="bpar0025">
<a id="o1270"></a>3. One percent to five percent of GCTs are extragonadal; they are generally less sensitive to chemotherapy and are more likely to contain yolk sac tumor elements than tumors arising in the testis.</li>
<li class="b1numlist" id="bpar0030">
<a id="o1275"></a>4. On rare occasion, teratomas may transform into somatic malignancies, such as rhabdomyosarcoma, adenocarcinoma, or neuroendocrine tumors.</li>
<li class="b1numlist" id="bpar0035">
<a id="o1280"></a>5. Two-thirds of patients with GCTs have diminished fertility.</li>
<li class="b1numlist" id="bpar0040">
<a id="o1285"></a>6. Choriocarcinomas and seminomas do not produce AFP.</li>
<li class="b1numlist" id="bpar0045">
<a id="o1290"></a>7. The half-life of AFP is 5 to 7 days, hCG is 24 to 36 hours, and LDH is 24 hours.</li>
<li class="b1numlist" id="bpar0050">
<a id="o1295"></a>8. The primary landing zone in the retroperitoneum for right testicular tumors is the interaortocaval lymph nodes; for left testicular tumors, it is the periaortic lymph nodes; the pattern of lymph drainage in the retroperitoneum is from right to left.</li>
<li class="b1numlist" id="bpar0055">
<a id="o1300"></a>9. Patients with persistently elevated AFP and hCG after orchiectomy are given induction chemotherapy.</li>
<li class="b1numlista" id="bpar0060">
<a id="o1305"></a>10. In clinical stage I disease, approximately 25% of patients will have metastases.</li>
<li class="b1numlista" id="bpar0065">
<a id="o1310"></a>11. Lymphovascular invasion and a prominent component of embryonal carcinoma are risk factors for metastases in NSGCTs.</li>
<li class="b1numlista" id="bpar0070">
<a id="o1315"></a>12. In seminomas, risk factors for metastases are rete testis involvement and tumor size greater than 4 cm.</li>
<li class="b1numlista" id="bpar0075">
<a id="o1320"></a>13. Patients with bulky retroperitoneal lymph node disease greater than 3 cm should receive induction chemotherapy.</li>
<li class="b1numlista" id="bpar0080">
<a id="o1325"></a>14. After initial treatment, patients with enlargement of a retroperitoneal mass or an increase in markers should undergo salvage chemotherapy. Consideration may be given to a CT-guided biopsy under selected circumstances.</li>
<li class="b1numlista" id="bpar0085">
<a id="o1330"></a>15. Patients with an NSGCT, undetectable markers, and a residual mass greater than 1 cm after chemotherapy should undergo surgical resection.</li>
<li class="b1numlista" id="bpar0090">
<a id="o1335"></a>16. Approximately half of those patients who have surgical resection of a retroperitoneal mass following chemotherapy will harbor teratoma or a viable malignancy. The remainder will have fibrosis.</li>
<li class="b1numlista" id="bpar0095">
<a id="o1340"></a>17. Patients with viable malignancy in residual masses after salvage chemotherapy have a poor prognosis.</li>
<li class="b1numlista" id="bpar0100">
<a id="o1345"></a>18. Predictors of relapse in patients with stage I seminoma on surveillance include rete testis invasion and size of tumor greater than 4 cm. Lymphovascular invasion is not predictive as it is in NSGCT.</li>
<li class="b1numlista" id="bpar0105">
<a id="o1350"></a>19. In patients with seminomas who are treated with chemotherapy, the size of the residual mass is highly predictive of viable tumor. Masses less than 3 cm rarely have viable tumor in them, whereas about a third of residual masses greater than 3 cm contain viable malignancy. FDG-PET is a useful adjunct to postchemotherapy staging CT to determine the need for postchemotherapy surgical resection. Residual masses larger than 3 cm that are PET negative and those less than 3 cm can be safely observed because of the high probability of necrosis/fibrosis.</li>
<li class="b1numlista" id="bpar0110">
<a id="o1355"></a>20. Late toxicity of chemotherapy includes peripheral neuropathy, Raynaud phenomenon, hearing loss, hypogonadism and infertility, secondary malignant neoplasms, and cardiovascular disease.</li>
<li class="b1numlista" id="bpar0115">
<a id="o1360"></a>21. There is an increased number of copies of genetic material from the short arm of chromosome 12 in germ cell tumors.</li>
<li class="b1numlista" id="bpar0120">
<a id="o1365"></a>22. There is no clinical distinction between immature and mature teratoma. Teratomas are resistant to chemotherapy. They also tend to be infiltrative when large and can be extremely difficult to resect.</li>
<li class="b1numlista" id="bpar0125">
<a id="o1370"></a>23. Of patients with testicular tumors, 52% are oligospermic and 10% are azoospermic at presentation.</li>
<li class="b1numlista" id="bpar0130">
<a id="o1375"></a>24. Of patients who receive radiation as treatment for intratubular germ cell neoplasia, 40% require testosterone supplementation.</li>
<li class="b1numlista" id="bpar0135">
<a id="o1380"></a>25. The risk for a secondary malignancy after radiation therapy for seminoma is 18% at 25 years.</li>
<li class="b1numlista" id="bpar0140">
<a id="o1385"></a>26. Ninety percent of Leydig cell tumors and Sertoli cell tumors are benign and 10% are malignant.</li>
<li class="b1numlista" id="bpar0145">
<a id="o1390"></a>27. The most common testicular neoplasm in men older than 50 years is lymphoma.</li>
<li class="b1numlista" id="bpar0150">
<a id="o1395"></a>28. Cystadenoma of the epididymis is associated with von Hippel-Lindau syndrome; adenomatoid tumor of the epididymis is benign.</li>
<li class="b1numlista" id="bpar0155">
<a id="o1400"></a>29. Liposarcoma is the most common paratesticular tumor in the adult. Rhabdomyosarcoma is the most common paratesticular tumor in the child.</li>
<li class="b1numlista" id="bpar0160">
<a id="o1405"></a>30. GCNIS is the common precursor lesion for all types of adult male GCT, with the exception of spermatocytic tumor.<a id="pg292"></a>
</li>
<li>
<span epub:type="pagebreak" title="292" id="pagebreak_292"></span>
</li>
<li class="b1numlista" id="bpar0165">
<a id="o1410"></a>31. Choriocarcinoma has a propensity for hematogenous dissemination. Yolk sac tumors in children are thought to spread hematogenously as well.</li>
<li class="b1numlista" id="bpar0170">
<a id="o1415"></a>32. Pure embryonal carcinoma may produce both AFP and hCG. Pure seminoma is associated with elevated serum hCG levels in 15% of cases but does not produce AFP. Pure teratoma typically is not associated with elevated serum tumor markers, although slightly elevated AFP levels may be observed. Choriocarcinoma is uniformly associated with elevated hCG levels but does not produce AFP. Most yolk sac tumors produce AFP, but they do not produce hCG.</li>
<li class="b1numlista" id="bpar0175">
<a id="o1420"></a>33. Testis-sparing surgery should be considered only in patients with suspected GCT who have normal testicular androgen production and who have a small (&lt;2 cm) tumor either in a solitary testis or in the setting of bilateral synchronous testicular GCT. Testis-sparing surgery should not be performed in patients with suspected GCT who have a normal contralateral testis. Testis-sparing surgery may also be considered in patients with suspected benign testicular lesions such as an epidermoid cyst or adenomatoid tumor arising from the tunica albuginea.</li>
<li class="b1numlista" id="bpar0180">
<a id="o1425"></a>34. Absence of teratoma in the primary tumor, prechemotherapy and postchemotherapy mass size, and percentage shrinkage of mass with chemotherapy are all associated with the presence of necrosis/fibrosis in residual masses after first-line chemotherapy. However, none of these factors (alone or together) is sufficiently accurate to exclude the presence of residual teratoma or viable malignancy in patients with residual masses greater than 1 cm.</li>
<li class="b1numlista" id="bpar0185">
<a id="o1430"></a>35. Approximately one-third of patients who have residual masses following chemotherapy will have residual masses at multiple anatomic sites (sites outside the retroperitoneum), and these patients should undergo resection of all sites of measurable residual disease because discordant histology between anatomic sites is reported in 22% to 46% of cases. However, the presence of necrosis in postchemotherapy RPLND specimens is highly predictive of necrosis at other sites outside the retroperitoneum.</li>
</ul>
</div>
</div>





<div class="pageavoid">
<figure class="fig" id="f0042">
<img src="../../IMAGES/B9780323639699000768/main.assets/f76-07-9780323639699.jpg" alt="image"/>
<figcaption class='figleg'>
<span class="fignum">Fig. 76.7</span>
</figcaption>
</figure>
</div>

<div class="pageavoid">
<figure class="fig" id="f0047">
<img src="../../IMAGES/B9780323639699000768/main.assets/f76-08-9780323639699.jpg" alt="image"/>
<figcaption class='figleg'>
<span class="fignum">Fig. 76.8</span>
</figcaption>
</figure>
</div>
</div>
</section>
</section>
</section><span id="f0041"></span><span id="f0046"></span>
</body>
</html>
